Allergan Urges 1st Circ. To Reverse Asacol Class Cert.

By Chuck Stanley (February 26, 2018, 9:35 PM EST) -- Allergan PLC urged the First Circuit on Friday to reverse the certification of a class of buyers of an anti-inflammatory drug, accusing the putative class of "bootstrapping" claims from purchasers of the drug in just four states to bring claims under dozens of other states' antitrust laws....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!